C12Q1/6811

TRANSCRIPTION FACTOR DECOYS, COMPOSITIONS AND METHODS
20180002740 · 2018-01-04 ·

Compositions and methods for identifying and using cis-regulatory and decoy sequences are disclosed.

TRANSCRIPTION FACTOR DECOYS, COMPOSITIONS AND METHODS
20180002740 · 2018-01-04 ·

Compositions and methods for identifying and using cis-regulatory and decoy sequences are disclosed.

Genome fractioning
11708606 · 2023-07-25 · ·

Disclosed herein are compositions and methods related to the elimination of molecules of a selected sequence from a nucleic acid sample or from an sequence dataset resulting from the sequencing of a sample, for example to exclude such molecules from downstream analysis or sequencing, or to exclude such sequences from a downstream data set.

Genome fractioning
11708606 · 2023-07-25 · ·

Disclosed herein are compositions and methods related to the elimination of molecules of a selected sequence from a nucleic acid sample or from an sequence dataset resulting from the sequencing of a sample, for example to exclude such molecules from downstream analysis or sequencing, or to exclude such sequences from a downstream data set.

Genome fractioning
11708606 · 2023-07-25 · ·

Disclosed herein are compositions and methods related to the elimination of molecules of a selected sequence from a nucleic acid sample or from an sequence dataset resulting from the sequencing of a sample, for example to exclude such molecules from downstream analysis or sequencing, or to exclude such sequences from a downstream data set.

Reduction of post-surgery cancer metastasis by combination of cannabidiol and NR2F6 inhibition
11712474 · 2023-08-01 · ·

Disclosed are means of stimulating systemic immunity and reduction of post-surgery tumor metastasis through the concurrent intralymphatic inhibition of NR2F6 and treatment with cannabidiol. In some embodiments NR2F6 is inhibited by high pressure transient delivery of short interfering RNA into tumor draining lymph nodes concurrent with systemic administration of cannabidiol. This combination may be performed together with means that induce immunogenic tumor cell death. Through the combination of immunogenic cell death and immune stimulation, the invention provides a means of enhancing the abscopal effect and in some embodiments to cause immunological mediated destruction primary and secondary neoplasia.

Reduction of post-surgery cancer metastasis by combination of cannabidiol and NR2F6 inhibition
11712474 · 2023-08-01 · ·

Disclosed are means of stimulating systemic immunity and reduction of post-surgery tumor metastasis through the concurrent intralymphatic inhibition of NR2F6 and treatment with cannabidiol. In some embodiments NR2F6 is inhibited by high pressure transient delivery of short interfering RNA into tumor draining lymph nodes concurrent with systemic administration of cannabidiol. This combination may be performed together with means that induce immunogenic tumor cell death. Through the combination of immunogenic cell death and immune stimulation, the invention provides a means of enhancing the abscopal effect and in some embodiments to cause immunological mediated destruction primary and secondary neoplasia.

IDENTIFICATION OF GENOMIC STRUCTURAL VARIANTS USING LONG-READ SEQUENCING
20230028445 · 2023-01-26 ·

Provided herein are systems and methods for detecting genomic structural variants using a non-application gene-editing sample preparation followed by long-read sequencing.

IDENTIFICATION OF GENOMIC STRUCTURAL VARIANTS USING LONG-READ SEQUENCING
20230028445 · 2023-01-26 ·

Provided herein are systems and methods for detecting genomic structural variants using a non-application gene-editing sample preparation followed by long-read sequencing.

Optimal selection method of gene chip probes for cancer screening

The invention relates to an optimal selection method of gene chip probes for cancer screening. The method is characterized in that the gene chip probes capable of being used for cancer screening are obtained through three stages of constructing a point mutation site (SNV) group, constructing a candidate probe group and verifying and confirming probes on the basis of nucleic acid data of a confirmed case of a selected cancer.